Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Attack -- A Complete Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Judy who wrote (14626)	8/16/1998 5:10:00 PM
From: flickerful	Respond to of 42787

re: big pharma judy. have a look at this...#reply-5373343 regards, randy

To: Judy who wrote (14626)	8/16/1998 5:23:00 PM
From: Claud B	Read Replies (1) \| Respond to of 42787

Judy, They have a marketing agreement with Zonagen for rights to Vasomax, an ED drug that promises to rival Viagra with fewer side effects. Vasomax NDA is currently before the FDA. That's one drug SGP has in the pipeline. Claud

To: Judy who wrote (14626)	8/16/1998 6:18:00 PM
From: Nancy	Respond to of 42787

I see you already got your answers from other well-informed posters. SGP's ED drug is developed by a small biotech firm in Houston. The side effects relating to blood pressure remain, except the new drug might not have side effect interfering vision. That is what I understand from reading news back in May. SGP also has the No.1 allergy drug Claritin - and with the abnormal weather we have had so far, it has been a blockbuster seller. It helps the bottom line a lot. (PFE held a distant No.2 position in this cat.)